Insider transactions

EDGAR

NextCure, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
19 transactions, 374,631 shares
Sum of shares × price per share: 1,852,320.25
Open-market sales (code S)
1 transactions, 30,000 shares
Sum of shares × price per share: 184,800

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–32 of 32

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-11-11 Filed 2026-11-13ADAR1 Capital Management, LLC 10% ownerSchneeberger Daniel 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)12,3335.0999
62,897.0667

Derived: shares × price per share. Exact value 62897.0667.

750,289Indirect (I) See FootnoteNo
F1, F2, F3
  • F1 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.0750 to $5.1000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  • F2 The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  • F3 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open filing 0001940272-26-000032 Read from the filing’s XML Dispute this row
2026-11-06 Filed 2026-11-09ADAR1 Capital Management, LLC 10% ownerSchneeberger Daniel 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)3,6625.1
18,676.2

Derived: shares × price per share. Exact value 18676.2.

737,956Indirect (I) See FootnoteNo
F1, F2
  • F1 The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  • F2 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open filing 0001940272-26-000030 Read from the filing’s XML Dispute this row
2026-11-05 Filed 2026-11-09ADAR1 Capital Management, LLC 10% ownerSchneeberger Daniel 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)1,0245.1
5,222.4

Derived: shares × price per share. Exact value 5222.4.

734,294Indirect (I) See FootnoteNo
F1, F2
  • F1 The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  • F2 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open filing 0001940272-26-000030 Read from the filing’s XML Dispute this row
2026-10-27 Filed 2026-10-27ADAR1 Capital Management, LLC 10% ownerSchneeberger Daniel 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)3,5535.0953
18,103.6009

Derived: shares × price per share. Exact value 18103.6009.

733,270Indirect (I) See FootnoteNo
F3, F4, F5
  • F3 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9900 to $5.1000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  • F4 The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  • F5 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open filing 0001940272-26-000029 Read from the filing’s XML Dispute this row
2026-10-26 Filed 2026-10-27ADAR1 Capital Management, LLC 10% ownerSchneeberger Daniel 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)1,6725.0344
8,417.5168

Derived: shares × price per share. Exact value 8417.5168.

729,717Indirect (I) See FootnoteNo
F2, F4, F5
  • F2 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.0000 to $5.1000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  • F4 The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  • F5 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open filing 0001940272-26-000029 Read from the filing’s XML Dispute this row
2026-10-23 Filed 2026-10-27ADAR1 Capital Management, LLC 10% ownerSchneeberger Daniel 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)5,6264.8294
27,170.2044

Derived: shares × price per share. Exact value 27170.2044.

728,045Indirect (I) See FootnoteNo
F1, F4, F5
  • F1 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.72 to $4.9000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  • F4 The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  • F5 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open filing 0001940272-26-000029 Read from the filing’s XML Dispute this row
2026-08-10 Filed 2026-08-12Simcere Zaiming, Inc. Other: Former 10% OwnerJiangsu Simcere Zaiming Pharmaceutical Co., Ltd. Other: Former 10% OwnerSimcere Zaiming Pharmaceutical Co., Ltd. Other: Former 10% OwnerSimcere Pharmaceutical Group Ltd Other: Former 10% OwnerRen Jinsheng Other: Former 10% OwnerTang Renhong Other: Former 10% Owner
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)30,0006.16
184,800

Derived: shares × price per share. Exact value 184800.00.

308,636Indirect (I) See FootnotesNo
F1, F2, F3
  • F1 The securities reported herein were directly held by Simcere Zaiming, Inc. (Simcere Zaiming) and may be deemed to have been indirectly beneficially owned by the other Reporting Persons.
  • F2 Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. (Jiangsu Zaiming) is the sole shareholder of Simcere Zaiming. Simcere Zaiming Pharmaceutical Co., Ltd. (formerly known as Hainan Simcere Zaiming Pharmaceutical Co., Ltd.) is the sole shareholder of Jiangsu Zaiming. Simcere Pharmaceutical Group Limited (Simcere Group) is the controlling shareholder of Simcere Zaiming Pharmaceutical Co., Ltd. through several intermediate companies. Mr. Jinsheng Ren is the chairman of the board of directors of Simcere Group and a director of Simcere Zaiming Pharmaceutical Co., Ltd. Mr. Renhong Tang is a director of Simcere Group, the chief executive officer and chairman of the board of directors of Simcere Zaiming Pharmaceutical Co., Ltd., a director of Jiangsu Zaiming and the chief executive officer and sole director of Simcere Zaiming. Messrs. Ren and Tang may be deemed to be the beneficial owners having shared voting power and shared investment power over the securities described herein.
  • F3 Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that any Reporting Person is the beneficial owner of any of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or for any other purpose.
Open filing 0001213900-26-088156 Read from the filing’s XML Dispute this row
2026-07-31 Filed 2026-08-03ADAR1 Capital Management, LLC 10% ownerSchneeberger Daniel 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)3,3004.9758
16,420.14

Derived: shares × price per share. Exact value 16420.1400.

689,416Indirect (I) See FootnoteNo
F4, F6, F7
  • F4 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9100 to $5.0000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  • F6 The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  • F7 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open filing 0001940272-26-000013 Read from the filing’s XML Dispute this row
2026-07-31 Filed 2026-08-03ADAR1 Capital Management, LLC 10% ownerSchneeberger Daniel 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)25,0004.9816
124,540

Derived: shares × price per share. Exact value 124540.0000.

714,416Indirect (I) See FootnoteNo
F5, F6, F7
  • F5 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9740 to $4.9824, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  • F6 The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  • F7 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open filing 0001940272-26-000013 Read from the filing’s XML Dispute this row
2026-07-31 Filed 2026-08-03ADAR1 Capital Management, LLC 10% ownerSchneeberger Daniel 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)8,0034.8
38,414.4

Derived: shares × price per share. Exact value 38414.4.

722,419Indirect (I) See FootnoteNo
F6, F7
  • F6 The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  • F7 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open filing 0001940272-26-000013 Read from the filing’s XML Dispute this row
2026-07-30 Filed 2026-08-03ADAR1 Capital Management, LLC 10% ownerSchneeberger Daniel 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)50,0004.9723
248,615

Derived: shares × price per share. Exact value 248615.0000.

443,266Indirect (I) See FootnoteNo
F1, F6, F7
  • F1 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9000 to $5.0000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  • F6 The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  • F7 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open filing 0001940272-26-000013 Read from the filing’s XML Dispute this row
2026-07-30 Filed 2026-08-03ADAR1 Capital Management, LLC 10% ownerSchneeberger Daniel 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)20,0005
100,000

Derived: shares × price per share. Exact value 100000.

463,266Indirect (I) See FootnoteNo
F6, F7
  • F6 The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  • F7 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open filing 0001940272-26-000013 Read from the filing’s XML Dispute this row
2026-07-30 Filed 2026-08-03ADAR1 Capital Management, LLC 10% ownerSchneeberger Daniel 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)20,0005
100,000

Derived: shares × price per share. Exact value 100000.

483,266Indirect (I) See FootnoteNo
F6, F7
  • F6 The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  • F7 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open filing 0001940272-26-000013 Read from the filing’s XML Dispute this row
2026-07-30 Filed 2026-08-03ADAR1 Capital Management, LLC 10% ownerSchneeberger Daniel 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)25,0004.8135
120,337.5

Derived: shares × price per share. Exact value 120337.5000.

508,266Indirect (I) See FootnoteNo
F2, F6, F7
  • F2 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.8100 to $4.8450, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  • F6 The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  • F7 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open filing 0001940272-26-000013 Read from the filing’s XML Dispute this row
2026-07-30 Filed 2026-08-03ADAR1 Capital Management, LLC 10% ownerSchneeberger Daniel 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)100,0004.9
490,000

Derived: shares × price per share. Exact value 490000.0.

608,266Indirect (I) See FootnoteNo
F6, F7
  • F6 The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  • F7 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open filing 0001940272-26-000013 Read from the filing’s XML Dispute this row
2026-07-30 Filed 2026-08-03ADAR1 Capital Management, LLC 10% ownerSchneeberger Daniel 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)77,8504.9556
385,793.46

Derived: shares × price per share. Exact value 385793.4600.

686,116Indirect (I) See FootnoteNo
F3, F6, F7
  • F3 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.7563 to $5.0000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  • F6 The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  • F7 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open filing 0001940272-26-000013 Read from the filing’s XML Dispute this row
2026-07-29 Filed 2026-07-29ADAR1 Capital Management, LLC 10% ownerSchneeberger Daniel 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)1,8105
9,050

Derived: shares × price per share. Exact value 9050.

391,666Indirect (I) See FootnoteNo
F2, F3
  • F2 The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  • F3 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open filing 0001940272-26-000012 Read from the filing’s XML Dispute this row
2026-07-29 Filed 2026-07-29ADAR1 Capital Management, LLC 10% ownerSchneeberger Daniel 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)1,6005
8,000

Derived: shares × price per share. Exact value 8000.

393,266Indirect (I) See FootnoteNo
F2, F3
  • F2 The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  • F3 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open filing 0001940272-26-000012 Read from the filing’s XML Dispute this row
2026-07-28 Filed 2026-07-29ADAR1 Capital Management, LLC 10% ownerSchneeberger Daniel 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)6,4004.9496
31,677.44

Derived: shares × price per share. Exact value 31677.4400.

389,856Indirect (I) See FootnoteNo
F1, F2, F3
  • F1 The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.9000 to $5.0000, inclusive. Each Reporting Person undertakes to provide to NextCure, Inc., any security holder of NextCure, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
  • F2 The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  • F3 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open filing 0001940272-26-000012 Read from the filing’s XML Dispute this row
2026-07-27 Filed 2026-07-29ADAR1 Capital Management, LLC 10% ownerSchneeberger Daniel 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)7,7984.9994
38,985.3212

Derived: shares × price per share. Exact value 38985.3212.

383,456Indirect (I) See FootnoteNo
F2, F3
  • F2 The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.
  • F3 For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Open filing 0001940272-26-000012 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-22Webster Stephen W Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (2,340) — exercise price 2.02
Acquired (A)2,3400—2,340Direct (D) No
F1
  • F1 The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.
Open filing 0000905148-26-003043 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-22Feigal Ellen Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (2,340) — exercise price 2.02
Acquired (A)2,3400—2,340Direct (D) No
F1
  • F1 The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.
Open filing 0000905148-26-003047 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-22Houston John G Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (2,340) — exercise price 2.02
Acquired (A)2,3400—2,340Direct (D) No
F1
  • F1 The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.
Open filing 0000905148-26-003046 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-22Jones Elaine V Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (2,340) — exercise price 2.02
Acquired (A)2,3400—2,340Direct (D) No
F1
  • F1 The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.
Open filing 0000905148-26-003045 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-22Borgman Anne Elizabeth Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (2,340) — exercise price 2.02
Acquired (A)2,3400—2,340Direct (D) No
F1
  • F1 The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.
Open filing 0000905148-26-003048 Read from the filing’s XML Dispute this row
2026-06-18 Filed 2026-06-22KABAKOFF DAVID S Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (3,510) — exercise price 2.02
Acquired (A)3,5100—3,510Direct (D) No
F1
  • F1 The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.
Open filing 0000905148-26-003044 Read from the filing’s XML Dispute this row
2026-01-30 Filed 2026-02-03Cobourn Steven P. Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (14,670) — exercise price 10.85
Acquired (A)14,6700—14,670Direct (D) No
F1
  • F1 One fourth of the option vests on January 30, 2027. The remainder vests in 36 monthly installments beginning on February 28, 2027.
Open filing 0000905148-26-000476 Read from the filing’s XML Dispute this row
2026-01-30 Filed 2026-02-03Guha Udayan Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (14,670) — exercise price 10.85
Acquired (A)14,6700—14,670Direct (D) No
F1
  • F1 One fourth of the option vests on January 30, 2027. The remainder vests in 36 monthly installments beginning on February 28, 2027.
Open filing 0000905148-26-000477 Read from the filing’s XML Dispute this row
2026-01-30 Filed 2026-02-03Mayer Timothy Officer: Chief Operating Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (14,670) — exercise price 10.85
Acquired (A)14,6700—14,670Direct (D) No
F1
  • F1 One fourth of the option vests on January 30, 2027. The remainder vests in 36 monthly installments beginning on February 28, 2027.
Open filing 0000905148-26-000478 Read from the filing’s XML Dispute this row
2026-01-30 Filed 2026-02-03Kundu Sourav Officer: Sr VP, Dev. Mfg.
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (8,270) — exercise price 10.85
Acquired (A)8,2700—8,270Direct (D) No
F1
  • F1 One fourth of the option vests on January 30, 2027. The remainder vests in 36 monthly installments beginning on February 28, 2027.
Open filing 0000905148-26-000479 Read from the filing’s XML Dispute this row
2026-01-30 Filed 2026-02-03Richman Michael Director · Officer: President CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (38,190) — exercise price 10.85
Acquired (A)38,1900—38,190Direct (D) No
F1
  • F1 One fourth of the option vests on January 30, 2027. The remainder vests in 36 monthly installments beginning on February 28, 2027.
Open filing 0000905148-26-000480 Read from the filing’s XML Dispute this row
2026-01-30 Filed 2026-02-03Shaw Kevin G. Officer: Sr VP, General Counsel
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (8,270) — exercise price 10.85
Acquired (A)8,2700—8,270Direct (D) No
F1
  • F1 One fourth of the option vests on January 30, 2027. The remainder vests in 36 monthly installments beginning on February 28, 2027.
Open filing 0000905148-26-000481 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.

Showing 1–33 of 33

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
ADAR1 Capital Management, LLC 722,419 SH3,619,319 dollarsNot in the prior quarter’s filings read Open filing 0001940272-26-000033 Filed 2026-11-16 Dispute this row
ADAGE CAPITAL PARTNERS GP, L.L.C. 377,202 SH1,889,782 dollarsHigher by 100,000 Prior quarter: 277,202Open filing 0001172661-26-005200 Filed 2026-11-16 Dispute this row
Affinity Asset Advisors, LLC 291,960 SH1,462,720 dollarsHigher by 250,000 Prior quarter: 41,960Open filing 0001011438-26-000687 Filed 2026-11-13 Dispute this row
Blackstone Inc. Partly reported under another manager224,000 SH1,122,240 dollarsNot in the prior quarter’s filings read Open filing 0001193125-26-463513 Filed 2026-11-16 Dispute this row
Sofinnova Investments, Inc. 222,654 SH1,115,497 dollarsUnchanged Prior quarter: 222,654Open filing 0001104659-26-128032 Filed 2026-11-16 Dispute this row
Eversept Partners, LP 185,455 SH929,130 dollarsNot in the prior quarter’s filings read Open filing 0001697013-26-000007 Filed 2026-11-16 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 156,842 SH785,778 dollarsUnchanged Prior quarter: 156,842Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
CITADEL ADVISORS LLC Partly reported under another manager110,660 SH554,407 dollarsNot in the prior quarter’s filings read Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row
Verition Fund Management LLC 92,946 SH465,659 dollarsNot in the prior quarter’s filings read Open filing 0001454027-26-000007 Filed 2026-11-13 Dispute this row
Soleus Capital Management, L.P. 90,000 SH450,900 dollarsNot in the prior quarter’s filings read Open filing 0001802630-26-000008 Filed 2026-11-16 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager78,144 SH391,526 dollarsHigher by 48,239 Prior quarter: 29,905Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
BANK OF AMERICA CORP /DE/ Partly reported under another manager75,035 SH375,925 dollarsNot in the prior quarter’s filings read Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager74,412 SH360,527 dollarsHigher by 74,351 Prior quarter: 61Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
JANE STREET GROUP, LLC Partly reported under another manager70,252 SH351,963 dollarsHigher by 37,527 Prior quarter: 32,725Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row
Pfizer Inc 44,357 SH225,334 dollarsHigher by 10 Prior quarter: 44,347Open filing 0000078003-26-000135 Filed 2026-11-12 Dispute this row
RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager39,148 SH196,131 dollarsLower by 132,054 Prior quarter: 171,202Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row
BlackRock, Inc. Partly reported under another manager36,820 SH184,468 dollarsLower by 528 Prior quarter: 37,348Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
MILLENNIUM MANAGEMENT LLC 26,526 SH132,895 dollarsLower by 61,586 Prior quarter: 88,112Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row
VANGUARD FIDUCIARY TRUST CO 24,761 SH124,053 dollarsHigher by 8,627 Prior quarter: 16,134Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
MORGAN STANLEY Partly reported under another manager22,932 SH114,889 dollarsHigher by 22,866 Prior quarter: 66Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
CARDIFF PARK ADVISORS, LLC 21,833 SH109,383 dollarsUnchanged Prior quarter: 21,833Open filing 0001398344-26-019783 Filed 2026-11-09 Dispute this row
PRUDENTIAL FINANCIAL INC Partly reported under another manager17,091 SH85,626 dollarsNot in the prior quarter’s filings read Open filing 0001137774-26-000233 Filed 2026-11-16 Dispute this row
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. Partly reported under another manager12,500 SH62,625 dollarsUnchanged Prior quarter: 12,500Open filing 0000905148-26-004861 Filed 2026-11-16 Dispute this row
CITIGROUP INC Partly reported under another manager12,284 SH61,543 dollarsNot in the prior quarter’s filings read Open filing 0000831001-26-000052 Filed 2026-11-04 Dispute this row
HRT FINANCIAL LP 12,020 SH60 dollarsLower by 24,430 Prior quarter: 36,450Open filing 0001475597-26-000249 Filed 2026-11-13 Dispute this row
ACADIAN ASSET MANAGEMENT LLC Partly reported under another manager10,664 SH53 dollarsLower by 8,318 Prior quarter: 18,982Open filing 0001140361-26-042753 Filed 2026-11-09 Dispute this row
UBS Group AG Partly reported under another manager6,028 SH30,200 dollarsHigher by 5,434 Prior quarter: 594Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
BARCLAYS PLC Partly reported under another manager5,629 SH28,201 dollarsLower by 97 Prior quarter: 5,726Open filing 0000312069-26-000241 Filed 2026-11-06 Dispute this row
EverSource Wealth Advisors, LLC 1,114 SH5,581 dollarsNot in the prior quarter’s filings read Open filing 0001710537-26-000009 Filed 2026-11-04 Dispute this row
SBI Securities Co., Ltd. 1,000 SH5,010 dollarsHigher by 980 Prior quarter: 20Open filing 0001851815-26-000004 Filed 2026-10-22 Dispute this row
Tower Research Capital LLC (TRC) Partly reported under another manager249 SH1,247 dollarsLower by 1,489 Prior quarter: 1,738Open filing 0001533421-26-000010 Filed 2026-11-16 Dispute this row
BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager32 SH160 dollarsUnchanged Prior quarter: 32Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row
Caitong International Asset Management Co., Ltd 18 SH90 dollarsNot in the prior quarter’s filings read Open filing 0001628280-26-068135 Filed 2026-10-29 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Ikarian Capital, LLC 288,303 SH
  • BOOTHBAY FUND MANAGEMENT, LLC 84,687 SH
  • Squadron Capital Management LLC 64,464 SH
  • Verdad Advisers, LP 60,451 SH
  • Virtu Financial LLC 10,991 SH
  • DIADEMA PARTNERS LP 7,742 SH
  • Persistent Asset Partners Ltd 1,981 SH
  • NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO 83 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Ikarian Capital, LLC Common Stock, $0.001 par value per share9.8500,282.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001778253-26-000011 Dispute this row
Neil Shahrestani Common Stock, $0.001 par value per share9.8500,282.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 2Open filing 0001778253-26-000011 Dispute this row
Affinity Asset Advisors, LLC Common Stock, $0.001 par value per share9.99475,626.0009/30/2026 Filed 2026-11-13SCHEDULE 13G/AAmendment 5Open filing 0001011438-26-000697 Dispute this row
Michael Cho Common Stock, $0.001 par value per share9.99475,626.0009/30/2026 Filed 2026-11-13SCHEDULE 13G/AAmendment 5Open filing 0001011438-26-000697 Dispute this row
JP Sailing Capital Ltd Common Stock, $0.001 par value per share9.9455,001.0009/30/2026 Filed 2026-10-20SCHEDULE 13GOpen filing 0002103371-26-000001 Dispute this row
Jianping Huang Common Stock, $0.001 par value per share9.9455,001.0009/30/2026 Filed 2026-10-20SCHEDULE 13GOpen filing 0002103371-26-000001 Dispute this row
ADAR1 Capital Management, LLC Common Stock, $0.001 par value per share15.8722,419.0007/31/2026 Filed 2026-08-14SCHEDULE 13GOpen filing 0001104659-26-097427 Dispute this row
Daniel Schneeberger Common Stock, $0.001 par value per share15.8722,419.0007/31/2026 Filed 2026-08-14SCHEDULE 13GOpen filing 0001104659-26-097427 Dispute this row
Squadron Master Fund LP Common Stock, $0.001 par value per share1.664,464.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0002050709-26-000024 Dispute this row
Squadron Capital Management LLC Common Stock, $0.001 par value per share1.664,464.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0002050709-26-000024 Dispute this row
Matthew Sesterhenn Common Stock, $0.001 par value per share1.664,464.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0002050709-26-000024 Dispute this row
William Blank Common Stock, $0.001 par value per share1.664,464.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0002050709-26-000024 Dispute this row
Ikarian Capital, LLC Common Stock, $0.001 par value per share9.99502,67206/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-352946 Dispute this row
Neil Shahrestani Common Stock, $0.001 par value per share9.99502,67206/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-352946 Dispute this row
Affinity Asset Advisors, LLC Common Stock, $0.001 par value per share6.4274,07306/30/2026 Filed 2026-08-13SCHEDULE 13G/AAmendment 4Open filing 0001011438-26-000507 Dispute this row
Michael Cho Common Stock, $0.001 par value per share6.4274,07306/30/2026 Filed 2026-08-13SCHEDULE 13G/AAmendment 4Open filing 0001011438-26-000507 Dispute this row
Adage Capital Management, L.P. Common Stock, par value $0.001 per share7.67277,202.0006/30/2026 Filed 2026-08-12SCHEDULE 13GOpen filing 0000919574-26-004977 Dispute this row
Robert Atchinson Common Stock, par value $0.001 per share7.67277,202.0006/30/2026 Filed 2026-08-12SCHEDULE 13GOpen filing 0000919574-26-004977 Dispute this row
Phillip Gross Common Stock, par value $0.001 per share7.67277,202.0006/30/2026 Filed 2026-08-12SCHEDULE 13GOpen filing 0000919574-26-004977 Dispute this row
SilverArc Capital Management, LLC Class A Common Stock4.9176,057.0003/31/2026 Filed 2026-05-13SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-060317 Dispute this row
Devesh Gandhi Class A Common Stock4.9176,057.0003/31/2026 Filed 2026-05-13SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-060317 Dispute this row
Affinity Asset Advisors, LLC Common Stock, $0.001 par value per share9.99348,60701/22/2026 Filed 2026-01-29SCHEDULE 13G/AAmendment 3Open filing 0001315863-26-000104 Dispute this row
Michael Cho Common Stock, $0.001 par value per share9.99348,60701/22/2026 Filed 2026-01-29SCHEDULE 13G/AAmendment 3Open filing 0001315863-26-000104 Dispute this row
Simcere Zaiming, Inc. Common Stock, par value $0.001 per share9.4338,636.0012/31/2025 Filed 2026-05-06SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-052993 Dispute this row
Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. Common Stock, par value $0.001 per share9.4338,636.0012/31/2025 Filed 2026-05-06SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-052993 Dispute this row
Simcere Zaiming Pharmaceutical Co., Ltd. Common Stock, par value $0.001 per share9.4338,636.0012/31/2025 Filed 2026-05-06SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-052993 Dispute this row
Simcere Pharmaceutical Group Limited Common Stock, par value $0.001 per share9.4338,636.0012/31/2025 Filed 2026-05-06SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-052993 Dispute this row
Ren Jinsheng Common Stock, par value $0.001 per share9.4338,636.0012/31/2025 Filed 2026-05-06SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-052993 Dispute this row
Tang Renhong Common Stock, par value $0.001 per share9.4338,636.0012/31/2025 Filed 2026-05-06SCHEDULE 13G/AAmendment 1Open filing 0001213900-26-052993 Dispute this row
Ikarian Capital, LLC Common Stock, $0.001 par value per share9.99363,03512/31/2025 Filed 2026-02-17SCHEDULE 13GOpen filing 0001193125-26-055156 Dispute this row
Neil Shahrestani Common Stock, $0.001 par value per share9.99363,03512/31/2025 Filed 2026-02-17SCHEDULE 13GOpen filing 0001193125-26-055156 Dispute this row
Squadron Master Fund LP Common Stock, $0.001 par value per share9.9271,127.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0002050709-26-000005 Dispute this row
Squadron Capital Management LLC Common Stock, $0.001 par value per share9.9271,127.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0002050709-26-000005 Dispute this row
Matthew Sesterhenn Common Stock, $0.001 par value per share9.9271,127.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0002050709-26-000005 Dispute this row
William Blank Common Stock, $0.001 par value per share9.9271,127.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0002050709-26-000005 Dispute this row
Pfizer Inc. (IRS Identification No.: 13-5315170) Common Stock par value $0.001 per share3.0157,646.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 1Open filing 0000078003-26-000018 Dispute this row
Pfizer Ventures (US) LLC (IRS Indentification No. 82-5524518 ) Common Stock par value $0.001 per share2.5131,109.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 1Open filing 0000078003-26-000018 Dispute this row
SilverArc Capital Management, LLC Class A Common Stock5.02176,057.0012/31/2025 Filed 2026-02-12SCHEDULE 13GOpen filing 0001104659-26-014076 Dispute this row
Devesh Gandhi Class A Common Stock5.02176,057.0012/31/2025 Filed 2026-02-12SCHEDULE 13GOpen filing 0001104659-26-014076 Dispute this row
Sofinnova Venture Partners IX, L.P. ("SVP IX") Common Stock, $0.001 par value7.1222,654.0012/19/2025 Filed 2026-03-05SCHEDULE 13D/AAmendment 2Open filing 0001104659-26-023741 Dispute this row
Sofinnova Management IX, L.L.C. ("SM IX") Common Stock, $0.001 par value7.1222,654.0012/19/2025 Filed 2026-03-05SCHEDULE 13D/AAmendment 2Open filing 0001104659-26-023741 Dispute this row
Dr. James I. Healy ("Healy") Common Stock, $0.001 par value7.1222,654.0012/19/2025 Filed 2026-03-05SCHEDULE 13D/AAmendment 2Open filing 0001104659-26-023741 Dispute this row
Squadron Master Fund LP Common Stock, $0.001 par value per share5.8154,021.0010/21/2025 Filed 2025-10-24SCHEDULE 13GOpen filing 0002050709-25-000009 Dispute this row
Squadron Capital Management LLC Common Stock, $0.001 par value per share6.5173,861.0010/21/2025 Filed 2025-10-24SCHEDULE 13GOpen filing 0002050709-25-000009 Dispute this row
Matthew Sesterhenn Common Stock, $0.001 par value per share6.5173,861.0010/21/2025 Filed 2025-10-24SCHEDULE 13GOpen filing 0002050709-25-000009 Dispute this row
William Blank Common Stock, $0.001 par value per share6.5173,861.0010/21/2025 Filed 2025-10-24SCHEDULE 13GOpen filing 0002050709-25-000009 Dispute this row
Affinity Healthcare Fund, LP Common Stock, par value $0.001 per share7.17191,882.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 2Open filing 0001999371-25-017894 Dispute this row
Affinity Asset Advisors, LLC Common Stock, par value $0.001 per share7.17191,882.0009/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 2Open filing 0001999371-25-017894 Dispute this row
Simcere Zaiming, Inc. Common Stock, par value $0.001 per share12.7338,636.0006/20/2025 Filed 2025-08-19SCHEDULE 13GOpen filing 0001213900-25-078679 Dispute this row
Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. Common Stock, par value $0.001 per share12.7338,636.0006/20/2025 Filed 2025-08-19SCHEDULE 13GOpen filing 0001213900-25-078679 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,748,233 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015164,615
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,828

Filings made before the SEC required XML are listed, not extracted.

Back to NextCure, Inc.